Selection of miRNAs for clopidogrel resistance prediction

This letter to the editor features a selection of possible miRNAs to be included into further development of smart diagnostic systems for clopidogrel resistance testing. The PharmGKB (www.pharmgkb.org), TargetScanHuman 7.2 (www.targetscan.org/vert_72/) databases were scanned for a selection of relevant miRNAs. The designed graph includes the miRNAs that cover most of the genes responsible for clopidogrel resistance. Twenty-three miRNAs were selected to be included into the smart clopidogrel resistance testing systems: miR-15 (9/132 cases, 6.8%), miR-16, miR-195, miR-203, miR-424, miR-497 (8/132 cases, 6.0%, each), miR-30 (6/132, 4.5%), miR-19, miR-155 (4/132 cases, 3.0% each), miR-26, miR-27, miR-223 (3/132 cases, 2.3% each), miR-31, miR-96, miR-101, miR-128, miR-129, miR-137, miR-138, miR-143, miR-200, miR-455, miR-1271, (2/132 cases, 1.5% each). This miRNAs selection can be used for scientific needs for further development of clopidogrel resistance testing systems. •A circos plot of microRNAs for future smart clopidogrel resistance testing system•MicroRNAs can serve as biomarkers for clopidogrel resistance.•MicroRNAs should target as many clopidogrel resistance genes as possible.